Evidence map›Paper›PMID 37367029›Full record

ArticleBiosensors2023

BPA Endocrine Disruptor Detection at the Cutting Edge: FPIA and ELISA Immunoassays.

Anna Raysyan, Sandro D Zwigart, Sergei A Eremin, Rudolf J Schneider

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Anna RaysyanBAM Federal Institute for Materials Research and Testing, 12205 Berlin, Germany.
Sandro D ZwigartFaculty III Process Sciences, Technische Universität Berlin, 10623 Berlin, Germany.
Sergei A EreminChemical Faculty, M.V. Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0002-6936-0720
Rudolf J SchneiderBAM Federal Institute for Materials Research and Testing, 12205 Berlin, Germany.ORCID 0000-0003-2228-1248
Federal Institute For Materials Research and Testing · DELomonosov Moscow State University · RUTechnische Universität Berlin · DE

Funding

BAM's MI-1 program BAM/BMWi Grant No. Ideen 2015 55 to A.R.
6 · The paper itself

Abstract

BPA is a chemical commonly used in the production of polymer-based materials that can have detrimental effects on the thyroid gland and impact human reproductive health. Various expensive methods, such as liquid and gas chromatography, have been suggested for detecting BPA. The fluorescence polarization immunoassay (FPIA) is an inexpensive and efficient homogeneous mix-and-read method that allows for high-throughput screening. FPIA offers high specificity and sensitivity and can be carried out in a single phase within a timeframe of 20-30 min. In this study, new tracer molecules were designed that linked the fluorescein fluorophore with and without a spacer to the bisphenol A moiety. To assess the influence of the C6 spacer on the sensitivity of an assay based on the respective antibody, hapten-protein conjugates were synthesized and assessed for performance in an ELISA setup, and this resulted in a highly sensitive assay with a detection limit of 0.05 g/L. The lowest limit of detection was reached by employing the spacer derivate in the FPIA and was 1.0 μg/L, working range from 2 to 155 μg/L. The validation of the methods was conducted using actual samples compared to LC-MS/MS, which served as the reference method. The FPIA and ELISA both demonstrated satisfactory concordance.

Indexed as

Endocrine DisruptorsChromatography, LiquidEnzyme-Linked Immunosorbent AssayFluorescence Polarization ImmunoassayHumansImmunoassayTandem Mass SpectrometryEndocrine Disruptorsbisphenol AELISAendocrine disruptorFPIAimmunoassay

Identifiers

PMID37367029
PMCPMC10296492
OpenAlexW4381248959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.